NCT00782561View on ClinicalTrials.gov

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

June 18, 2009

Study Completion Date

June 18, 2009

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG

FG-3019

FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks

Trial Locations (3)

11040

New Hyde Park

43205

Columbus

27599-7155

Chapel Hill

Sponsors

Lead Sponsor

FibroGen
All Listed Sponsors
lead

FibroGen

INDUSTRY

NCT00782561 - Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) | Biotech Hunter | Biotech Hunter